The pharmaceutical firm has transferred China-based business development director Manabu Aruga to its Tokyo headquarters where he will oversee corporate VC deals in Asia.
Japan-headquartered biotechnology producer Eisai has appointed Manabu Aruga, formerly China-based business development director, as strategic investment officer covering Japan and Asia for its Corporate Venture Investment (CVI) division.
His new role will involve Aruga relocating to Eisai’s headquarters in Tokyo and leading CVI’s investment initiatives. He will collaborate with chief strategy officer Kazumasa Nagayama and chief financial officer Ryohei Yanagi to strengthen the unit’s corporate venturing strategies.
Formed in May 2019, CVI is armed with approximately $137m in capital and…
